FDA approves janson Balversa (erdafitinib) to be marketed for treatment in adult patients with advanced or metastatic bladder cancer

bladder cancer is the sixth most common cancer in the United States, with the most common bladder cancer being urinary skin cancerBladder cancer is usually associated with genetic mutations in the skin cells of the patient's bladder or urineMutations in fibroblast growth factor receptors (FGFR) occur in about one in five patients with recurrent/refractory bladder cancerrecently,the FDA's(http://announced the accelerated approval of the listing of Balversa, acompany owned by Johnson and Johnson,
http:// for the treatment of adult patients with late or metastatic bladder cancer who are still developing the disease after platinum-based chemotherapythis is the first TARGETED treatment approved by the FDA for metastatic bladder cancerabout Erdafitinib
Erdafitinib is an oral pan-FGFR inhibitorFGFRs is a family of receptor tyrosine kinases whose genetic mutations in different tumors can cause them to be activated, thus promoting the survival and proliferation of tumor cellsErdafitinib has been awarded a breakthrough treatment by the FDA, and thedrug(http://ofnew drugs
(http:// has also been eligible for priority reviewThethis approval is based on the performance of erdafitinib in phase 2 clinicaltrial(http://in 87 patients with advanced or metastatic bladder cancerThese patients carry specific FGFR3 or FGFR2 gene mutationsin these patients who had received chemotherapy and continued to develop the disease, erdafitinib achieved a total remission rate of 32.2%, of which 2.3% achieved complete remissionThe average duration of remission in patients reached 5.4 monthsTwenty-five percent of these patients received anti-PD-L1/PD-1 therapy, and erdafitinib also had an effect on patients who did not respond to PD-L1/PD-1 therapy